Biotech Values

[DewDiligence]

>> gnta does show that relying on big pharma validation is no guarantee. ave wasted a lot of $ on them. <<

AVE may have struck out with REGN too. Considering the amount of money they put into the VEGF-trap deal, we aren’t hearing much about the drug these days.

Most of us know not to buy groceries on an empty stomach. In the same vein, AVE should have known not to cut a deal while everyone was drooling over drugs targeting VEGF, as they were in the summer of 03.